64
Participants
Start Date
July 31, 2011
Primary Completion Date
February 29, 2012
Study Completion Date
February 29, 2012
PF-05175157 or Placebo
One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
PF-05175157 or Placebo
One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
PF-05175157 or Placebo
One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
PF-05175157 or Placebo
One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
PF-05175157 or Placebo
One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
Miami Research Associates, South Miami
MRA Clinical Research, South Miami
Pulmonary Physicians of South Florida, South Miami
Lead Sponsor
Pfizer
INDUSTRY